Related references
Note: Only part of the references are listed.AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
K. H. Baumann et al.
ANNALS OF ONCOLOGY (2012)
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Ignacio Romero et al.
ENDOCRINOLOGY (2012)
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Michael A. Gold et al.
GYNECOLOGIC ONCOLOGY (2012)
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
Agustin A. Garcia et al.
GYNECOLOGIC ONCOLOGY (2012)
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube
Ignacio Romero Noguera et al.
GYNECOLOGIC ONCOLOGY (2012)
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.
Ignace B. Vergote et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Stan B. Kaye et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Low-grade serous carcinomas of the ovary contain very few point mutations
Sian Jones et al.
JOURNAL OF PATHOLOGY (2012)
Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response
Yu-Li Chen et al.
MOLECULAR ONCOLOGY (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer
G. K. Siddiqui et al.
ANGIOGENESIS (2011)
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
J. J. Biagi et al.
ANNALS OF ONCOLOGY (2011)
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer
Katherine M. Bell-McGuinn et al.
GYNECOLOGIC ONCOLOGY (2011)
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study
Lubomir Bodnar et al.
GYNECOLOGIC ONCOLOGY (2011)
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies
Lydia Usha et al.
GYNECOLOGIC ONCOLOGY (2011)
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group
K. Baumann et al.
GYNECOLOGIC ONCOLOGY (2011)
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
Kian Behbakht et al.
GYNECOLOGIC ONCOLOGY (2011)
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
Daniela Matei et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study
Jason A. Konner et al.
CLINICAL CANCER RESEARCH (2010)
Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
Christina M. Annunziata et al.
CLINICAL CANCER RESEARCH (2010)
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
Helen J. Mackay et al.
EUROPEAN JOURNAL OF CANCER (2010)
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Michael Friedlander et al.
GYNECOLOGIC ONCOLOGY (2010)
Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Mullerian Tumors
Richard T. Penson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Sharmila Makhija et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Kuan-Ting Kuo et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Novel Agents on the Horizon for Cancer Therapy
Wen W. Ma et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
Carol Aghajanian et al.
GYNECOLOGIC ONCOLOGY (2009)
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
Russell J. Schilder et al.
GYNECOLOGIC ONCOLOGY (2009)
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
Ursula A. Matulonis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Joshua Z. Press et al.
BMC CANCER (2008)
The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis
Caroline A. Heckman et al.
CANCER RESEARCH (2008)
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Susan C. Modesitt et al.
GYNECOLOGIC ONCOLOGY (2008)
Folate receptor alpha as a tumor target in epithelial ovarian cancer
Kimberly R. Kalli et al.
GYNECOLOGIC ONCOLOGY (2008)
Expression of hypoxia-inducible factor 1α gene affects the outcome in patients with ovarian cancer
R. Shimogai et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Sporadic epithelial ovarian cancer: Clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway
Johanne I. Weberpals et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Russell J. Schilder et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Low-Grade Serous Ovarian Cancer: a Unique Disease
Kathleen M. Schmeler et al.
CURRENT ONCOLOGY REPORTS (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer - A phase II clinical study with proteomic profiling
Edwin M. Posadas et al.
CANCER (2007)
A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer
J. P. Micha et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)
D. S. Alberts et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Alternate molecular genetic pathways in ovarian carcinomas of common histological types
Julia Willner et al.
HUMAN PATHOLOGY (2007)
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer
Edwin M. Posadas et al.
CANCER (2007)
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies
M. V. Seiden et al.
GYNECOLOGIC ONCOLOGY (2007)
Clinical activity of Pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
Michael S. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The role of folate receptor α in cancer development, progression and treatment:: Cause, consequence or innocent bystander?
Linda E. Kelemen
INTERNATIONAL JOURNAL OF CANCER (2006)
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers
RL Coleman et al.
GYNECOLOGIC ONCOLOGY (2006)
Role of folate receptor genes in reproduction and related cancers
H Elnakat et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2006)
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study
AN Gordon et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer
S Campos et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic oncology group study
RJ Schilder et al.
CLINICAL CANCER RESEARCH (2005)
AZD2171:: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
SR Wedge et al.
CANCER RESEARCH (2005)
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential
I Meinhold-Heerlein et al.
ONCOGENE (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas
CY Hsu et al.
CLINICAL CANCER RESEARCH (2004)
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
DA Altomare et al.
ONCOGENE (2004)
Mutation of the PIK3CA gene in ovarian and breast cancer
IG Campbell et al.
CANCER RESEARCH (2004)
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma
ML Gemignani et al.
GYNECOLOGIC ONCOLOGY (2003)
Ovarian cancer: Strategies for overcoming resistance to chemotherapy
R Agarwal et al.
NATURE REVIEWS CANCER (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
RE Bristow et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Angiogenesis in ovarian cancer
MR Brown et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2000)
Share Paper
